Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Total Liabilities (2019 - 2025)

Lyell Immunopharma (LYEL) has disclosed Total Liabilities for 7 consecutive years, with $91.8 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 14.98% to $91.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $91.8 million through Dec 2025, down 14.98% year-over-year, with the annual reading at $91.8 million for FY2025, 14.98% down from the prior year.
  • Total Liabilities hit $91.8 million in Q4 2025 for Lyell Immunopharma, up from $78.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $334.0 million in Q1 2021 to a low of $78.8 million in Q3 2025.
  • Historically, Total Liabilities has averaged $133.5 million across 5 years, with a median of $98.0 million in 2023.
  • Biggest five-year swings in Total Liabilities: tumbled 49.37% in 2023 and later increased 13.63% in 2024.
  • Year by year, Total Liabilities stood at $197.6 million in 2021, then crashed by 47.22% to $104.3 million in 2022, then dropped by 8.85% to $95.1 million in 2023, then increased by 13.63% to $108.0 million in 2024, then dropped by 14.98% to $91.8 million in 2025.
  • Business Quant data shows Total Liabilities for LYEL at $91.8 million in Q4 2025, $78.8 million in Q3 2025, and $86.5 million in Q2 2025.